clinical trial · NCT04306237
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
Imbria Pharmaceuticals, Inc.·phase2·withdrawn
Refractory AnginaIMB-1018972Placebo oral tablet
brief summary
The objectives of the study are to assess the safety, tolerability, and potential efficacy of IMB-1018972 on patients with refractory angina. Study will assess functional capacity employing a modified Bruce Protocol treadmill ETT, patient reports of angina symptoms via an electronic diary, and activity using an accelerometer.
started
May 1, 2020
primary completion
Feb 1, 2025
completion
Apr 1, 2025
last updated
Nov 10, 2025
official title
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol